The Multi-Biomarker Disease Activity (MBDA) score in RA, for example, combines CRP, IL-6, TNF-R1, and MMP-3 to assess disease activity and predict treatment response more effectively than individual biomarkers. This evidence concerns the gene TNFRSF1A and rheumatoid arthritis.